Cancer Family
Uveal Melanocytic Neoplasm
CI-CAN-00000381Explore in graph →
Non-malignant59 active trials1 approved drugs17 evidence items
- NCIt
- C205057
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000381Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05308901 | Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma | terminated | Phase 2 | 6 | Providence Health & ServicesOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03712904 |
| Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma |
| terminated |
| Phase 2 |
| 3 |
| Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER |
| 1 |
| Sep 24, 2025 |
| clinicaltrials |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Thomas Jefferson UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01801358 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 38 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 6 | Sep 16, 2020 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00482911 | Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma | terminated | Phase 2 | 12 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 27, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Aug 12, 2026source: clinicaltrials